Specialised Commissioning in the NHS – What do you need to know now

Pharma Market Access Insights - from Mtech Access

The proposed new NHSE systems for specialised commissioning are arguably the highest risk of all current dynamics, both for the NHS and for suppliers. Key aspects or policy have been published in ways that are hard to access and even harder to interpret. Here, we gather an expert panel to discuss what proposed new NHSE systems for specialised commissioning mean in practice.
In this episode, we explore:
- What’s new for Specialised Commissioning and what’s set to change?
- What are the potential implications of the proposed changes recently published?
- Integrated Care Boards (ICBs) and their increasing role with Specialised Commissioning
- What this means for the NHS and for industry in practice
The episode begins with an overview and analysis of the changes from David Thorne (Principal Associate, Mtech Access and Business Development Director, Well Up North PCN). David then opens up a broader discussion about the implications of these changes with our guest panellists James Curtis (Deputy Operational Director, Gloucestershire NHS Foundation Trust) and Mohammed Asghar (ICS Prescribing Governance Lead at Frimley Health and Care ICS).
The episode was originally broadcast as a live webinar on 2nd December 2022.
Learn more at: https://mtechaccess.co.uk/specialised-commissioning-nhs/
Find our more about our NHS Insight and Interaction services

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.